FDA authorizes limited prescriptions of Paxlovid by pharmacists
The Food and Drug Administration today authorized state-licensed pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) to patients as a treatment for those at high risk of severe COVID-19. Because Paxlovid must be taken within five days of symptom onset, the change could spur expanded access and more-timely treatment of eligible patients. The change was made through an amended emergency use authorization.
Related News Articles
Headline
The AHA's Living Learning Network is partnering with the Centers for Disease Control and Prevention to launch the Sepsis Champions Leadership Series. These…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Centers for Disease Control and Prevention today released an advisory recommending clinicians expedite subtyping of type A influenza samples from…
Headline
The San Francisco Department of Public Health Jan. 10 announced a presumptive positive case of H5N1 bird flu in a child after they experienced symptoms of…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Louisiana Department of Health yesterday announced that a patient hospitalized last month for H5N1 bird flu has died, becoming the first U.S. death from…